GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kangmei Pharmaceutical Co Ltd (SHSE:600518) » Definitions » Revenue

Kangmei Pharmaceutical Co (SHSE:600518) Revenue : ¥4,931 Mil (TTM As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kangmei Pharmaceutical Co Revenue?

Kangmei Pharmaceutical Co's revenue for the three months ended in Mar. 2024 was ¥1,201 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥4,931 Mil. Kangmei Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was ¥0.16. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.47.

Warning Sign:

Kangmei Pharmaceutical Co Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Kangmei Pharmaceutical Co was 46.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -28.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was -25.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Kangmei Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 59.80% per year. The lowest was -50.50% per year. And the median was 12.40% per year.


Kangmei Pharmaceutical Co Revenue Historical Data

The historical data trend for Kangmei Pharmaceutical Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kangmei Pharmaceutical Co Revenue Chart

Kangmei Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11,445.55 5,412.01 4,152.52 4,180.15 4,874.02

Kangmei Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,143.95 1,233.06 1,157.12 1,339.90 1,201.24

Competitive Comparison of Kangmei Pharmaceutical Co's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Kangmei Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kangmei Pharmaceutical Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kangmei Pharmaceutical Co's Revenue distribution charts can be found below:

* The bar in red indicates where Kangmei Pharmaceutical Co's Revenue falls into.



Kangmei Pharmaceutical Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4,931 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kangmei Pharmaceutical Co  (SHSE:600518) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Kangmei Pharmaceutical Co Revenue Related Terms

Thank you for viewing the detailed overview of Kangmei Pharmaceutical Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kangmei Pharmaceutical Co (SHSE:600518) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Taike Road, Xiameilin, Futian District, Shenzhen, CHN, 518000
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the manufacturing, research and marketing of herbal medicine and chemical raw materials.
Executives
Xu Dong Jin Director
Li Jian Hua senior management
Qiu Xi Wei Director
Wang Min senior management
Peng Qin senior management
Ma Xing Tian Director
Lin Guo Xiong senior management
Zhuang Yi Qing senior management
Wen Shao Sheng Supervisors

Kangmei Pharmaceutical Co (SHSE:600518) Headlines

No Headlines